BioSenic SA
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
BIOS | BR
Overview
Corporate Details
- ISIN(s):
- BE0970179827 (+1 more)
- LEI:
- 549300HFIIMTOP1DFR76
- Country:
- Belgium
- Address:
- RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
- Website:
- http://www.biosenic.com/
Description
BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-04-29 07:00 |
PR_2021-04-29_BOTHE_FY 2020_FR_Final_Long.pdf
|
French | PDF • 363.5 KB | ||
| 2021-03-01 09:00 |
20210226_BOTHE_Acte-Notaire_S36C-6e21022612020.pdf
|
French | PDF • 394.9 KB | ||
| 2021-02-09 07:00 |
2FR.20210226_BOTHE_Procuration_ AGE.pdf
|
French | PDF • 570.9 KB | ||
| 2021-02-09 07:00 |
3EN.Bone Therapeutics_EGM 26 February 2021_Information on shareholders_ rights.…
|
English | PDF • 333.9 KB | ||
| 2021-02-09 07:00 |
3FR.Bone Therapeutics_AGE 26 février 2021_information_sur_les_droits_des_action…
|
French | PDF • 201.1 KB | ||
| 2021-02-09 07:00 |
1EN.20210226_BOTHE_Convocation EGM EN.pdf
|
English | PDF • 142.4 KB | ||
| 2021-02-09 07:00 |
BOTHE_Bilan résumé_2020-12-31_AGE.pdf
|
French | PDF • 50.8 KB | ||
| 2021-02-09 07:00 |
2EN.20210226_BOTHE_Proxy form_ EGM.pdf
|
English | PDF • 635.6 KB | ||
| 2021-02-09 07:00 |
1FR.20210226_BOTHE_Convocation AGE FR.pdf
|
French | PDF • 190.3 KB | ||
| 2021-02-09 07:00 |
PR_2021-02-09_BOTHE_EGM2_Notice_EN_Final.pdf
|
English | PDF • 177.8 KB | ||
| 2021-02-09 07:00 |
PR_2021-02-09_BOTHE_EGM2_Notice_FR_Final.pdf
|
French | PDF • 192.8 KB | ||
| 2021-02-08 12:00 |
20210208_BOTHE_Acte-Notaire_S36C-6e21020811020.pdf
|
French | PDF • 275.8 KB | ||
| 2021-01-20 07:00 |
Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook
|
English | PDF • 212.6 KB | ||
| 2021-01-20 07:00 |
Bone Therapeutics fait le point sur son activité du quatrième trimestre 2020 et…
|
French | PDF • 219.2 KB | ||
| 2021-01-12 07:00 |
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
|
English | PDF • 186.1 KB |
Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioSenic SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioSenic SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-16 | Rieger Francois | Board | Sell | 2,500,000 | 25,000.00 EUR |
| 2024-08-06 | Rieger Francois | Board | Sell | 868,653 | 7,186.87 EUR |
| 2024-08-05 | POMI SCHNEITER VERONIQUE | Board | Sell | 534,750 | 4,331.47 EUR |
| 2024-08-02 | POMI SCHNEITER VERONIQUE | Board | Sell | 193,900 | 1,609.37 EUR |
| 2024-08-01 | Rieger Francois | Board | Sell | 1,236,684 | 11,463.87 EUR |
| 2024-08-01 | POMI SCHNEITER VERONIQUE | Board | Sell | 140,003 | 1,246.03 EUR |
| 2024-07-31 | POMI SCHNEITER VERONIQUE | Board | Sell | 503,771 | 4,685.07 EUR |
| 2024-07-30 | POMI SCHNEITER VERONIQUE | Board | Sell | 360,021 | 3,348.20 EUR |
| 2024-07-29 | POMI SCHNEITER VERONIQUE | Board | Sell | 372,893 | 3,430.62 EUR |
| 2024-07-24 | POMI SCHNEITER VERONIQUE | Board | Sell | 2,168,361 | 21,033.10 EUR |
Peer Companies
